Krishnansu S. Tewari, MD, discusses the excitement around immunotherapy in cervical cancer.
Krishnansu S. Tewari, MD, associate professor, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine, discusses the excitement around immunotherapy in cervical cancer.
Scientifically, it makes sense to look at these therapies in this setting, Tewari says. The mutational burden of cervical cancer is similar to other solid tumors where immunotherapy has had positive results, according to phase III findings.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More